1.Bispectral index-guided propofol sedation during endoscopic ultrasonography
Ayana OKAMOTO ; Ken KAMATA ; Takeshi MIYATA ; Tomoe YOSHIKAWA ; Rei ISHIKAWA ; Tomohiro YAMAZAKI ; Atsushi NAKAI ; Shunsuke OMOTO ; Kosuke MINAGA ; Kentaro YAMAO ; Mamoru TAKENAKA ; Yasutaka CHIBA ; Toshiharu SAKURAI ; Naoshi NISHIDA ; Masayuki KITANO ; Masatoshi KUDO
Clinical Endoscopy 2022;55(4):558-563
Background/Aims:
Bispectral index (BIS) monitors process and display electroencephalographic data are used to assess the depth of anesthesia. This study retrospectively evaluated the usefulness of BIS monitoring during endoscopic ultrasonography (EUS).
Methods:
This study included 725 consecutive patients who underwent EUS under sedation with propofol. BIS monitoring was used in 364 patients and was not used in 361. The following parameters were evaluated: (1) median dose of propofol; (2) respiratory and circulatory depression; (3) occurrence of body movements; (4) awakening score >8 at the time; and (5) awakening score 2 hours after leaving the endoscopy room.
Results:
The BIS group received a significantly lower median dose of propofol than the non-BIS group (159.2 mg vs. 167.5 mg; p=0.015) in all age groups. For patients aged ≥75 years, the reduction in heart rate was significantly lower in the BIS group than in the non-BIS group (1.2% vs. 9.1%; p=0.023). Moreover, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5% vs. 39.4%; p<0.001).
Conclusions
During EUS examination, BIS monitoring is useful for maintaining a constant depth of anesthesia, especially in patients 75 years of age or older.
2.Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.
Yasutaka YAMADA ; Shinichi SAKAMOTO ; Yoshiyasu AMIYA ; Makoto SASAKI ; Takayuki SHIMA ; Akira KOMIYA ; Noriyuki SUZUKI ; Koichiro AKAKURA ; Tomohiko ICHIKAWA ; Hiroomi NAKATSU
Asian Journal of Andrology 2018;20(5):432-437
The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml-1), intermediate (100-999 ng ml-1), and high (≥1000 ng ml-1). All patients received androgen deprivation therapy (ADT) immediately. We investigated PSA progression-free survival (PFS) for first-line ADT and overall survival (OS) within each of the three groups. Furthermore, we analyzed response to antiandrogen withdrawal (AW) and alternative antiandrogen (AA) therapies after development of castration-resistant prostate cancer (CRPC). No significant differences in OS were observed among the three groups (P = 0.654). Patients with high PSA levels had significantly short PFS for first-line ADT (P = 0.037). Conversely, patients in the high PSA level group had significantly longer PFS when treated with AW than those in the low PSA level group (P = 0.047). Furthermore, patients with high PSA levels had significantly longer PFS when provided with AA therapy (P = 0.049). PSA responders to AW and AA therapies had significantly longer survival after CRPC development than nonresponders (P = 0.011 and P < 0.001, respectively). Thus, extremely high PSA level predicted favorable response to vintage sequential ADT and AW. The current data suggest a novel aspect of extremely high PSA value as a favorable prognostic marker after development of CRPC.
Aged
;
Aged, 80 and over
;
Androgen Antagonists/therapeutic use*
;
Disease Progression
;
Humans
;
Male
;
Middle Aged
;
Prognosis
;
Progression-Free Survival
;
Prostate-Specific Antigen/blood*
;
Prostatic Neoplasms/mortality*
;
Treatment Outcome